<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125553</url>
  </required_header>
  <id_info>
    <org_study_id>NN5401-1980</org_study_id>
    <secondary_id>U1111-1113-7011</secondary_id>
    <nct_id>NCT01125553</nct_id>
  </id_info>
  <brief_title>A Comparison Between Two Formulations of NN5401 in Healthy Subjects</brief_title>
  <official_title>A Trial to Test for Bioequivalence Between Two NN5401 Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America (USA). The aim of the trial is to
      compare the exposure of two formulations of insulin degludec/insulin aspart (NN5401) in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum insulin degludec concentration-time curve</measure>
    <time_frame>from 0 to 120 hours after single-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum insulin degludec concentration</measure>
    <time_frame>from 0 to 120 hours after single-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum insulin aspart concentration-time curve</measure>
    <time_frame>from 0 to 12 hours after single-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum insulin aspart concentration</measure>
    <time_frame>from 0 to 12 hours after single-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum insulin degludec concentration</measure>
    <time_frame>from 0 to 120 hours after single-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum insulin aspart concentration</measure>
    <time_frame>from 0 to 12 hours after single-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IDegAsp B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDegAsp F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/insulin aspart</intervention_name>
    <description>Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).</description>
    <arm_group_label>IDegAsp B</arm_group_label>
    <arm_group_label>IDegAsp F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Considered generally healthy upon completion of medical history, physical examination,
             vital signs and electrocardiogram (ECG), as judged by the physician

          -  Body mass index between 18.0 and 27.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to trial start

          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent
             per day)

          -  Not able or willing to refrain from smoking and use of nicotine gum or transdermal
             nicotine patches during the inpatient period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

